Interleukin-10 |
| |
Authors: | Dr Michel Goldman Thierry Velu Marina Pretolani |
| |
Institution: | 1. Department of Immunology, H?pital Erasme, and Laboratory of Experimental Immunology, Université Libre de Bruxelles, 8-1070, Bruxelles, Belgium 2. Department of Medical Genetics, H?pital Erasme, and IRIBHN, Université Libre de Bruxelles, Bruxelles, Belgium 3. Unité de Pharmacologie Cellulaire, Unité Associée INSERM U285, Institut Pasteur, Paris, France
|
| |
Abstract: | Interleukin-10 (IL-10) is a potent anti-inflammatory and immunosuppressive cytokine secreted by several cell types. Most anti-inflammatory effects of IL-10 are caused by its ability to deactivate macrophages and monocytes, whereas its immunosuppressive properties are due to functional inhibition of both antigen-presenting cells and T cells. On the other hand, IL-10 also exerts immunostimulatory effects, especially on B cells, CD8+ cytotoxic T cells and natural killer cells. In vivo administration of recombinant IL-10 (rIL-10) efficiently prevents experimental septic shock induced by endotoxin, staphylococcal superantigen or cecal ligation and puncture, as well as experimental autoimmune diseases mediated by T helper type 1 (T(H)1) cells and other inflammatory disorders. rIL-10 exerts paradoxical effects in cancer models, where it promotes tumour rejection, probably due to its stimulatory properties on cytotoxic cells. On the other hand, rIL-10 increases the severity of experimental infections caused by fungi or bacteria, and enhances systemic autoimmune features in mice with spontaneous lupus syndrome. Although the therapeutic potential of rIL-10 in human diseases seems promising, the multiple facets of rIL-10 in experimental immunopathology indicate that the success of clinical trials with rIL-10 will depend both on the appropriate selection of the patient populations to be treated and on the early detection of possible adverse effects. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|